Preclinical rationale for combining the Smac-mimetic Debio 1143 with concurrent chemioradiotherapy in LA-SCCHN

D. Viertl (1), F. Perillo-Adamer (1), S. Rigotti (2), H. Maby El Hajjami (2), A. Vaslin (2), G. Vuagniaux (2), C Zanna (2), Oscar Matzinger (1)

Presented at ICHNO 2013 in Barcelona, Spain

1. Laboratory of Radiation Oncology, Lausanne, Switzerland
2. Debiopharm SA, Lausanne, Switzerland